Researchers at Stanford University have discovered that donor-specific anti-HLA antibodies can be used to detect and treat graft-versus-host disease (GVHD) in transplant recipients after allogenic transplantation.
Stanford researchers have engineered hematopoietic stem cells to provide long-term secretion of chosen therapeutic antibodies, eliminating the need of repeated dosing for delivery.
Researchers at Stanford have developed a method of preventing Graft versus Host Disease (GVHD) by inhibiting a specific immune receptor. GVHD is a major debilitating complication of transplantation.